The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals

Abstract

Drug-drug interactions are a recurring problem in immunocompromised patients treated with triazole antifungals. While the introduction of new antifungals has expanded opportunities for lowering drug toxicity, virtually all antifungal regimens carry the risk of pharmacokinetic and pharmacodynamic interaction. This review presents the published data on molecular determinants (enzymes, transporters, orphan nuclear receptors) of systemic triazole pharmacokinetics in humans, including itraconazole, fluconazole, voriconazole and posaconazole. Systemic triazoles are inhibitors of cytochrome P450 (CYP) isozymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees. In addition, some are substrates and/or inhibitors of drug transporters such as multidrug resistance-1 gene product, P-glycoprotein, or breast cancer resistance protein. The interactions of triazole antifungals can be divided into the following categories: modifications of antifungal pharmacokinetics by other drugs, modifications of other drug pharmacokinetics by antifungals, and two-way interactions. These features are the basis of most interactions that occur during triazole therapy.

Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk

“…These include azole antifungal agents such as ketoconazole, macrolide antibiotics such as troleandomycin, HIV protease inhibitors such as saquinavir, antidepressants such as fl uoxetine, and furanocoumarin, 6',7'-dihydroxybergamottin found in grapefruit juice (174)(175)(176). CYP3A4 enzyme is also highly inducible by many drugs and dietary chemicals.…”

Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics

“…12 Drugs metabolised by the same CYP enzymes often interact, 13,14 and several websites detail the role of CYP enzymes in drug interactions (for example, http:// bioinformatics.charite.de/supercyp/index.php?site ¼ home, http://medicine.iupui.edu/clinpharm/ddis/ and http://www. drugbank.ca/).…”

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

“…8 Of the antimycotic drugs used for the treatment of invasive aspergillosis, voriconazole poses a high risk for pharmacokinetic DDIs, as it is a known substrate and inhibitor of several cytochrome P450 isozymes (CYP), for example, CYP 2C19, 2C9 and 3A4. [9][10][11] Nivoix et al 10 considered voriconazole as a moderately strong CYP inhibitor, showing a two to fivefold increase in area under the curve values of sensitive CYP 3A4 substrates. Immunosuppressants such as CYA, sirolimus and tacrolimus are commonly used in HSCT recipients and are known substrates of CYP 3A4.…”